Analyst Price Forecast Suggests 33.80% Upside As of April 2, 2025, the average one-year price target for Ascendis Pharma A is $211.82/share. The forecasts range from a low of $163.62 to a high of ...

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $192.00. Discover outperforming stocks and ...

The United States market has shown robust performance recently, rising 8.4% in the last week with all sectors gaining ground, and achieving a 5.9% increase over the past year, while earnings are ...

Has Ascendis Pharma A/S (ASND) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Ascendis Pharma A/S is one of 1003 companies in the ...

Ascendis Pharma A/S (Nasdaq: NASDAQ:ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food &... On Thursday, UBS reaffirmed its Buy rating and $196.00 price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Ascendis Pharma (ASND) have fared rather well during recent market volatility and particularly the downturn in the biotech sector. The YTD gain of +10% contrasts nicely to -17% for the ...

“Hi, I’m Elon,” said one speaker, in a reader-submitted video posted to Palo Alto Online (via Tom’s Hardware). “Can we be friends? Will you be my friend? I’ll give you a ...

The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down or a recession. The ...